Conv. Plasma
Nigella Sativa
Peg.. Lambda

All favipiravir studies
Meta analysis
Home COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 68% Improvement Relative Risk Favipiravir  Behboodikhah et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 2,174 patients in Iran Lower mortality with favipiravir (not stat. sig., p=0.2) Behboodikhah et al., Iranian J. Scienc.., Sep 2022 Favors favipiravir Favors control

Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz

Behboodikhah et al., Iranian Journal of Science and Technology, Transactions A: Science, doi:10.1007/s40995-022-01351-0
Sep 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 2,174 hospitalized patients showing significantly shorter length of stay with favipiravir treatment.
This study includes remdesivir and favipiravir.
risk of death, 68.5% lower, OR 0.32, p = 0.20, treatment 95, control 2,079, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Behboodikhah et al., 15 Sep 2022, retrospective, Iran, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz
Hooman Behboodikhah, Eslam Shorafa, Iman Karimzadeh, Mohsen Moghadami, Javad Shahmohammadi, Mohsen Bayati, Khosro Keshavarz, Manica Negahdaripour
patients in critical conditions are hospitalized and treated with various protocols including antiviral drugs, which have been updated repeatedly. This study was aimed to analyze the demographics, costs, and outcomes of drug regimens in COVID-19 patients hospitalized in ''Ali Asghar'' hospital, affiliated with Shiraz University of Medical Sciences, from March 2019 to December 2020 as a retrospective study, approved by the ethics committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1399.1003) on Dec. 28, 2020. Using hospital information system (HIS) data, 2174 patients receiving favipiravir, remdesivir, interferon-b, and Kaletra Ò were analyzed. Descriptive, univariate, and regression analyses were used. The costs and consequences of different drug regimens were significantly different (P value \ 0.05); the highest and lowest costs belonged to remdesivir and Kaletra Ò , respectively. The highest and lowest mean length of stay and mortality were related to remdesivir and favipiravir, respectively. Mortality did not differ significantly with various regimens. Length of stay was significantly shorter with favipiravir and Kaletra Ò than interferon-b. Remdesivir had significantly the highest cost. Age presented a significantly positive relationship with mortality and length of stay. Besides, ICU admission significantly increased mortality, length of stay, and costs. Underlying diseases and low blood oxygen saturation contributed to mortality. COVID-19 correlation with age and underlying diseases is accordant with the published data. Given the highest costs and broad usage of remdesivir, besides controversies regarding its outcomes and side effects, a stricter evaluation of remdesivir benefits seems essential. Totally, COVID-19 therapeutic protocols should be selected carefully to optimize costs and outcomes.
Author Contributions KHK and MN: contributed to the study conception and design. HB, KHK, and MN: were involved in data colstatistical analysis, interpretation, manuscript drafting, and final review of the manuscript. MM, ESH, and IK: helped with the research idea, providing the data, and supervision of the research. JSH: helped in data collecting and data cleaning. MB: helped in statistical analysis and interpretation. All authors have read and approved the final manuscript. Declarations Conflict of Interest The authors declare no competing interests. Authors and Affiliations
Bagheri, Moezzi, Mosaddeghi, Interferoninducer antivirals: potential candidates to combat COVID-19, Int Immunopharmacol
Barbarawi, Jabri, Kumar, Fashanu, Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials, Contemp Clin Trials
Bartsch, Ferguson, Mckinnell, Shea, Wedlock, The potential health care costs and resource use associated with COVID-19 in the United States, Health Aff
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19-final report, New Eng J Med
Cai, Yang, Liu, Chen, Shu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering
Cao, Wang, Wen, Liu, Wang, A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19, New Eng J Med
Chen, Dai, Mo, Li, Ma, Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a single-centered, Retrosp Study J Gerontol: Series A
Dawoud, Soliman, Cost-effectiveness of antiviral treatments for pandemics and outbreaks of respiratory illnesses, including COVID-19: a systematic review of published economic evaluations, Value Health
Doggrell, Remdesivir, a remedy or a ripple in severe COVID-19?, Expert Opin Investig Drugs
Dro_, Rosik, Lechowicz, Machaj, Szostak et al., An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment, Drug Resist Updat
Elshabrawy, SARS-CoV-2: an update on potential antivirals in light of SARS-CoV antiviral drug discoveries, Vaccines
Ghaffaridarab, Keshavarz, Sadeghi, Shahmohamadi, Kavosi, The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran, BMC Health Serv Res
Grein, Ohmagari, Shin, Diaz, Asperges, Compassionate use of remdesivir for patients with severe Covid-19, N Eng J Med
Guan, Liang, Zhao, Liang, Chen, Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis, Eur Res J
Hashemian, Pourhanifeh, Hamblin, Shahrzad, Mirzaei, Rd inhibitors and COVID-19: Is molnupiravir a good option?, Biomed Pharmacother
Jo, Jamieson, Edoka, Long, Silal, Costeffectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa, Open Forum Inf Diss, doi:10.1093/ofid/ofab040
Li, Geng, Peng, Meng, Lu, Molecular immune pathogenesis and diagnosis of COVID-19, J Pharm Anal
Lotfi, Rezaei, SARS-CoV-2: a comprehensive review from pathogenicity of the virus to clinical consequences, J Med Virol
Mahase, Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports, BMJ
Martines, Ritter, Matkovic, Gary, Bollweg, Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States, Emerg Infect Dis
Molina, Seow, Heng, Chong, Ho, Outcomes of direct and indirect medical intensive care unit admissions from the emergency department of an acute care hospital: a retrospective cohort study, BMJ Open
Monk, Marsden, Tear, Brookes, Batten, Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Resp Med
Mosaddeghi, Shahabinezhad, Dehghani, Farahmandnejad, Taghipour et al., Therapeutic approaches for COVID-19 based on the interferon-mediated immune responses, Curr Signal Transduct Ther
Nasir, Perveen, Murshed, Nazneen, Talha, Survival and biomarkers of COVID-19 patients treated with remdesivir and favipiravir in ICU during the peak of pandemic: a single center study in Bangladesh, JPRI
Negahdaripour, Post-COVID-19 hyperglycemia: a concern in selection of therapeutic regimens, Iran J Med Sci
Negahdaripour, The rise and fall in therapeutic candidates for COVID-19, Iran J Med Sci
Owji, Negahdaripour, Hajighahramani, Immunotherapeutic approaches to curtail COVID-19, Int Immunopharmacol
Parashkouhi, Mosaddeghi, Bagheri, Moezzi, Hoseini, The dual sides of interferon induction in COVID-19 treatment, Trend Pharm Sci
Park, Iwasaki, Type I and Type III interferons-induction, signaling, evasion, and application to combat COVID-19, Cell Host Microbe
Perlman, Another decade, another coronavirus, N Eng J Med
Sanchez-Felipe, Vercruysse, Sharma, Ma, Lemmens, A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate, Nature
Sepandi, Taghdir, Alimohamadi, Afrashteh, Hosamirudsari, Factors associated with mortality in COVID-19 patients: a systematic review and meta-analysis, Iran J Public Health
Shen, Yang, Zhao, Jiang, Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement, W J Pediatr
Singh, COVID-19 and its impact on society, Electron Res J Soc Sci
Singh, Chugh, Khera, Chugh, Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis, BMJ Open
Spinner, Gottlieb, Criner, Arribaslo ´pez Jr, Cattelan, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Srinivas, Sacha, Koval, Antivirals for COVID-19, Cleve Clin J Med, doi:10.3949/ccjm.87a.ccc030
V'kovski, Kratzel, Steiner, Stalder, Thiel, Coronavirus biology and replication: implications for SARS-CoV-2, Nat Rev Microbiol
Walmsley, Bernstein, King, Arribas, Beall, Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection, N Eng J Med
Wise, Covid-19: remdesivir is recommended for authorisation by European Medicines Agency
Yamamura, Matsuura, Nakagawa, Fukuoka, Domi, Effect of favipiravir and an anti-inflammatory strategy for COVID-19, Crit Care
Zhang, Lu, Wang, Jia, Li, Do underlying cardiovascular diseases have any impact on hospitalised patients with COVID-19?, Heart
Zhou, Chen, Shannon, Wei, Xiang, Interferon-a2b treatment for COVID-19, Front Immunol, doi:10.3389/fimmu.2020.01061
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop